The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
advancedpregabalinneuropathic painrenal impairmentbipolar disorderlamotriginedose adjustmentcognitive side effects
A 58-year-old male with bipolar II disorder stabilized on lamotrigine 200 mg daily and a history of diabetic peripheral neuropathy was started on pregabalin 75 mg twice daily eight weeks ago for burning neuropathic pain in both feet rated 8 out of 10 on a visual analog scale. The dose was titrated to 150 mg twice daily at week four. At today's evaluation, his pain has decreased to 5 out of 10, and he reports reduced burning and electric shock sensations. However, he describes new cognitive symptoms including word-finding difficulty, mental fogginess, and trouble concentrating at work. His PHQ-9 is 6, unchanged from before pregabalin initiation, and his mood cycling has remained stable on lamotrigine. His wife notes he seems sedated in the evenings and has had two episodes of stumbling on stairs. Renal function shows a creatinine clearance of 62 mL/min. The PMHNP is evaluating the risk-benefit balance of pregabalin in this clinical context. Which of the following best represents the appropriate evaluation?
Explanation
Evaluating gabapentinoid efficacy and toxicity in patients with renal impairment requires dose adjustment based on creatinine clearance, as pregabalin is almost exclusively renally eliminated. Cognitive and motor adverse effects in patients with reduced renal function should prompt evaluation for supratherapeutic drug levels before concluding medication intolerance or failure.
Key Takeaway
Pregabalin adverse effects in patients with reduced creatinine clearance should be evaluated as potential dose-related toxicity from impaired renal elimination, and renal dosing adjustment should precede any conclusions about the medication's risk-benefit ratio.